急性脑梗死溶栓后应用低分子肝素治疗临床研究

A CLINICAL STUDY OF LOW-MOLECULAR-WEIGHT HEPARINS FOR TREAMENT OF ACUTE CEREBRAL INFARCTION AFTER THROMBOLYTIC THERAPY

目的 :观察急性脑梗死溶栓后应用低分子肝素治疗临床效果与可行性。方法 :选取急性脑梗死溶栓后病人 5 2例 ,随机分为治疗组 (n =2 6 )与对照组 (n =2 6 )。对照组给予常规治疗。治疗组在常规治疗的基础上于溶栓 2h内给予低分子肝素治疗 ,疗程 7d。结果 :治疗组总显效率 (基本治愈 +显著进步 )明显优于对照组 (P<0 .0 1) ,神经功能平分下降显著高于对照组 (P <0 .0 1)。并且无并发深静脉血栓 (DVT)者 ,未发现自发性出血及其他不良反应。结论 :急性脑梗死溶栓后应用低分子肝素治疗 ,能预防再梗死 ,显著减少梗死病人DVT的发病率。改善病人预后且安全可靠、简便易用 ,值得临床进一步推广应用。

Objective:To observe the clinical effects and feasibility of low-molecular-weight heparins (LMWH) therapy in the acute cerebral infarction (ACI) after using thrombolytic urokinase (UK).Methods: 52 cases suffered from ACI were randomly divided into LMWH group (n=26) and control group (n=26). Control group was treated with routine therapy. LMWH group was treated with routine therapy + LMWH within 2 hours after thrombolytic therapy, the therapeutic course was 7 days.Result:Clinical total effective rate (basically cure + significantly improvement) and the reduction in the scale of neurological deficit in the LMWH group were significantly higher than control group (P<0.01). DVT and other side effects were not found in the LMWH group.Conclusion:This method can prevent cerebrum from infarction again and significantly reduced the incidence rate of DVT and can improve the prognosis of patients, it is safe, convenient and worth further clinical application.